C i i T E C H Labs is our joint venture with leading metabolic researcher Dr Yossi Tam and ‘Yissum’ the tech transfer arm of the Hebrew University.

C i i T E C H LtdC i i T E C H is a cannabis biotech company that focuses on discovering, developing and commercializing therapeutic cannabis products. By collaborating with leading research institutions in Israel and local suppliers in the UK & the EU, C i i T E C H leverages the full potential of Israel’s cutting-edge cannabis innovation. C i i T E C H has developed and marketed Provacan, one of the leading UK CBD health brands.

Dr Yossi Tam: Head of Obesity & Metabolism Laboratory, Hadassah. Dr Tam is Scientific Advisory Board Member at, Phytecs, Therapix, Europacific Medical, SADE Ltd, BioNanoSim Ltd Hospital, Jerusalem. The Obesity and Metabolism Laboratory is focused on uncovering the involvement of the endocannabinoid system in the pathogenesis of obesity and its metabolic complications, with therapeutic prospects for the development of an effective drug therapy.

Hebrew University: The Hebrew University School of Pharmacy’s Multidisciplinary Center for Cannabinoid Research is integrating, coordinating and conducting this exciting research on cannabinoids, endocannabinoids and medical cannabis.

Yissum: Founded in 1964, Yissum is the technology transfer company of The Hebrew University. Since inception, Yissum has registered 10,000+ patents covering 3,000+ inventions; licensed 950+ technologies and produced 150+ spin-off companies including; Mobileye, Orcam and Briefcam. Yissum’s global business partners include companies such as Novartis, Merck, Intel, Google and many more.

Why Israel?

The Rich History of Cannabis: For over 50 years, Israel has been at the forefront of scientific cannabis research and trials. Led by Prof. Raphael Mechoulam at the Hebrew University in Jerusalem, Israeli scientists have unlocked many secrets of the plant including THC, CBD and the endocannabinoid system.

To this day Israel continues to lead the world in cannabis research.

Start Up Nation & Industry Ecosystems: Israel is well known for its entrepreneurial attitude towards research and innovation. From Ag-Tech to Med-Tech, cannabis fits perfectly with Israel’s dynamic entrepreneurial culture.

National Regulatory System: Israel was one of the first countries in the world to approve a government supported medical cannabis program for terminal and post traumatic veterans.

Why Cannabis?

Medical cannabis is cannabis and cannabinoids for the primary use of attempting to treat or cure an indication. When used without THC and other psychoactive compounds, cannabis can support general health and wellness similar to widely used vitamins and minerals that are prescribed by physicians for their patients and that are readily available in pharmacies and health food shops.

The use of cannabis as medicine has not been rigorously tested due to regulatory restrictions, resulting in limited clinical research to define the safety and efficacy. Preliminary evidence suggests that cannabis can reduce nausea and vomiting during chemotherapy, improve appetite in people with HIV/AIDS, reduce chronic pain and muscle spasms and can treat severe forms of epilepsy.

Why Obesity?​

Obesity is a chronic disease that is now reaching epidemic proportions [1], with more than one-third of U.S. adults that are considered obese. It has been described as a catalyst for cardiovascular disease, type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD).

NAFL is a major cause of morbidity and mortality in Western societies [2]. The indication describes a spectrum of liver conditions ranging from ectopic accumulation of fat in the liver (hepatic steatosis) to non-alcoholic steatohepatitis (NASH).

Several lines of evidence suggest that NAFLD promotes type 2 diabetes mellitus (T2DM). While NAFLD is present in 20-30% of the general population [4], it reaches the impressive prevalence of 50-75% of patients affected by T2DM [5].

Conversely, insulin resistance, which occurs in 66-83% of patients with NAFLD, promotes hepatic lipid accumulation and liver injury. Once T2DM is fully developed, it further contributes to the development of steatosis, NASH, fibrosis, cirrhosis and HCC.
To date, NAFLD is considered as a promising, new predictive marker for T2DM, with potential therapeutic implications. Therefore, diagnostic and early therapeutic interventions are needed for treating NAFLD patients at risk for developing T2DM.

References:

  1. Randall, M.D., D.A. Kendall, and S. O’Sullivan, The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol, 2004. 142(1): p. 20-6.
  2. Angulo, P., Nonalcoholic fatty liver disease. Rev Gastroenterol Mex, 2005. 70 Suppl 3: p. 52-6.
  3. van den Berghe, G., The role of the liver in metabolic homeostasis: implications for inborn errors of metabolism. J Inherit Metab Dis, 1991. 14(4): p. 407-20.
  4. de Alwis, N.M. and C.P. Day, Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol, 2008. 48 Suppl 1: p. S104-12.
  5. Gupte, P., et al., Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol, 2004. 19(8): p. 854-8.

FOLLOW US

Follow us and enjoy up to date information on the medical cannabis industry together with cannabinoid research and product development.